Titre : Lévorphanol

Lévorphanol : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Pathways
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Lévorphanol : Questions médicales les plus fréquentes", "headline": "Lévorphanol : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Lévorphanol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-13", "dateModified": "2025-03-10", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Lévorphanol" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Morphinanes", "url": "https://questionsmedicales.fr/mesh/D009019", "about": { "@type": "MedicalCondition", "name": "Morphinanes", "code": { "@type": "MedicalCode", "code": "D009019", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.723.795" } } }, "about": { "@type": "MedicalCondition", "name": "Lévorphanol", "alternateName": "Levorphanol", "code": { "@type": "MedicalCode", "code": "D007981", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ali Haider", "url": "https://questionsmedicales.fr/author/Ali%20Haider", "affiliation": { "@type": "Organization", "name": "Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA." } }, { "@type": "Person", "name": "Akhila Reddy", "url": "https://questionsmedicales.fr/author/Akhila%20Reddy", "affiliation": { "@type": "Organization", "name": "Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. asreddy@mdanderson.org." } }, { "@type": "Person", "name": "Valerie Le Rouzic", "url": "https://questionsmedicales.fr/author/Valerie%20Le%20Rouzic", "affiliation": { "@type": "Organization", "name": "From the Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York." } }, { "@type": "Person", "name": "Ankita Narayan", "url": "https://questionsmedicales.fr/author/Ankita%20Narayan", "affiliation": { "@type": "Organization", "name": "From the Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York." } }, { "@type": "Person", "name": "Amanda Hunkle", "url": "https://questionsmedicales.fr/author/Amanda%20Hunkle", "affiliation": { "@type": "Organization", "name": "From the Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Category-specific and category-general neural codes of recognition memory in the ventral visual pathway.", "datePublished": "2023-04-29", "url": "https://questionsmedicales.fr/article/37207411", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cortex.2023.04.004" } }, { "@type": "ScholarlyArticle", "name": "The features analysis of hemoglobin expression on visual information transmission pathway in early stage of Alzheimer's disease.", "datePublished": "2024-07-08", "url": "https://questionsmedicales.fr/article/38972885", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-64099-0" } }, { "@type": "ScholarlyArticle", "name": "Disrupted third visual pathway function in schizophrenia: Evidence from real and implied motion processing.", "datePublished": "2024-01-26", "url": "https://questionsmedicales.fr/article/38309185", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nicl.2024.103570" } }, { "@type": "ScholarlyArticle", "name": "Causal effect of COVID-19 on optic nerve and visual pathway disorders: genetic evidence of lung-brain axis.", "datePublished": "2024-07-16", "url": "https://questionsmedicales.fr/article/39081310", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1440262" } }, { "@type": "ScholarlyArticle", "name": "Retinal structure and visual pathway function at school age in children born extremely preterm: a population-based study.", "datePublished": "2023-07-01", "url": "https://questionsmedicales.fr/article/37393251", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12886-023-03055-4" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés polycycliques", "item": "https://questionsmedicales.fr/mesh/D011083" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures aromatiques polycycliques", "item": "https://questionsmedicales.fr/mesh/D011084" }, { "@type": "ListItem", "position": 4, "name": "Phénanthrènes", "item": "https://questionsmedicales.fr/mesh/D010616" }, { "@type": "ListItem", "position": 5, "name": "Morphinanes", "item": "https://questionsmedicales.fr/mesh/D009019" }, { "@type": "ListItem", "position": 6, "name": "Lévorphanol", "item": "https://questionsmedicales.fr/mesh/D007981" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Lévorphanol - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Lévorphanol", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Lévorphanol", "description": "Comment diagnostiquer une douleur nécessitant du lévorphanol ?\nQuels tests sont utilisés pour évaluer la douleur ?\nLe lévorphanol est-il prescrit pour tous les types de douleur ?\nQuels critères déterminent l'utilisation du lévorphanol ?\nLe lévorphanol est-il utilisé en cas de douleur chronique ?", "url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Visual+Pathways&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Lévorphanol", "description": "Quels sont les effets secondaires du lévorphanol ?\nLe lévorphanol peut-il provoquer des réactions allergiques ?\nQuels symptômes indiquent une surdose de lévorphanol ?\nComment reconnaître une dépendance au lévorphanol ?\nLe lévorphanol peut-il affecter l'humeur ?", "url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Visual+Pathways&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Lévorphanol", "description": "Comment prévenir les effets secondaires du lévorphanol ?\nQuelles précautions prendre avant de commencer le lévorphanol ?\nLe lévorphanol est-il sûr pour les personnes âgées ?\nComment éviter la dépendance au lévorphanol ?\nQuelles alternatives au lévorphanol existent ?", "url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Visual+Pathways&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Lévorphanol", "description": "Comment le lévorphanol est-il administré ?\nQuelle est la posologie habituelle du lévorphanol ?\nLe lévorphanol peut-il être combiné avec d'autres analgésiques ?\nQuels sont les risques d'un traitement prolongé au lévorphanol ?\nComment arrêter le lévorphanol en toute sécurité ?", "url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Visual+Pathways&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Lévorphanol", "description": "Quelles complications peuvent survenir avec le lévorphanol ?\nLe lévorphanol peut-il interagir avec d'autres médicaments ?\nComment gérer une réaction allergique au lévorphanol ?\nQuels sont les signes d'une surdose de lévorphanol ?\nLe lévorphanol peut-il causer des problèmes cardiaques ?", "url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Visual+Pathways&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Lévorphanol", "description": "Qui est à risque de dépendance au lévorphanol ?\nLes jeunes adultes sont-ils plus à risque avec le lévorphanol ?\nQuels facteurs augmentent le risque d'effets secondaires ?\nLe lévorphanol est-il risqué pour les femmes enceintes ?\nLes personnes ayant des problèmes respiratoires sont-elles à risque ?", "url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Visual+Pathways&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une douleur nécessitant du lévorphanol ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic se fait par évaluation clinique et historique médical du patient." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la douleur ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des échelles de douleur et des examens physiques sont utilisés pour évaluer l'intensité." } }, { "@type": "Question", "name": "Le lévorphanol est-il prescrit pour tous les types de douleur ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, il est principalement utilisé pour la douleur modérée à sévère, pas pour la douleur légère." } }, { "@type": "Question", "name": "Quels critères déterminent l'utilisation du lévorphanol ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent l'intensité de la douleur et la réponse aux traitements antérieurs." } }, { "@type": "Question", "name": "Le lévorphanol est-il utilisé en cas de douleur chronique ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être utilisé pour la douleur chronique lorsque d'autres traitements échouent." } }, { "@type": "Question", "name": "Quels sont les effets secondaires du lévorphanol ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent la somnolence, la constipation et des nausées." } }, { "@type": "Question", "name": "Le lévorphanol peut-il provoquer des réactions allergiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réactions allergiques peuvent survenir, bien que rares." } }, { "@type": "Question", "name": "Quels symptômes indiquent une surdose de lévorphanol ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent la dépression respiratoire, la somnolence excessive et la confusion." } }, { "@type": "Question", "name": "Comment reconnaître une dépendance au lévorphanol ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes de dépendance incluent le besoin compulsif de médicament et des symptômes de sevrage." } }, { "@type": "Question", "name": "Le lévorphanol peut-il affecter l'humeur ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut provoquer des changements d'humeur, y compris l'euphorie ou la dépression." } }, { "@type": "Question", "name": "Comment prévenir les effets secondaires du lévorphanol ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance régulière et l'ajustement de la posologie peuvent aider à prévenir les effets secondaires." } }, { "@type": "Question", "name": "Quelles précautions prendre avant de commencer le lévorphanol ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Informez votre médecin de vos antécédents médicaux et des médicaments que vous prenez." } }, { "@type": "Question", "name": "Le lévorphanol est-il sûr pour les personnes âgées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Il doit être utilisé avec prudence chez les personnes âgées en raison du risque accru d'effets secondaires." } }, { "@type": "Question", "name": "Comment éviter la dépendance au lévorphanol ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Utilisez-le uniquement selon les prescriptions et évitez l'auto-médication." } }, { "@type": "Question", "name": "Quelles alternatives au lévorphanol existent ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des alternatives incluent d'autres analgésiques opioïdes ou des traitements non opioïdes." } }, { "@type": "Question", "name": "Comment le lévorphanol est-il administré ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il est généralement administré par voie orale ou intraveineuse selon la situation clinique." } }, { "@type": "Question", "name": "Quelle est la posologie habituelle du lévorphanol ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La posologie varie, mais commence souvent à 2-4 mg toutes les 6-8 heures selon la douleur." } }, { "@type": "Question", "name": "Le lévorphanol peut-il être combiné avec d'autres analgésiques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être utilisé en association avec d'autres analgésiques pour un meilleur contrôle de la douleur." } }, { "@type": "Question", "name": "Quels sont les risques d'un traitement prolongé au lévorphanol ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement prolongé peut entraîner une tolérance, une dépendance et des effets secondaires accrus." } }, { "@type": "Question", "name": "Comment arrêter le lévorphanol en toute sécurité ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'arrêt doit être progressif sous supervision médicale pour éviter les symptômes de sevrage." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le lévorphanol ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la dépression respiratoire, la constipation sévère et la dépendance." } }, { "@type": "Question", "name": "Le lévorphanol peut-il interagir avec d'autres médicaments ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut interagir avec d'autres médicaments, augmentant le risque d'effets indésirables." } }, { "@type": "Question", "name": "Comment gérer une réaction allergique au lévorphanol ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "En cas de réaction allergique, arrêtez le médicament et consultez immédiatement un médecin." } }, { "@type": "Question", "name": "Quels sont les signes d'une surdose de lévorphanol ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent la somnolence extrême, la confusion et la difficulté à respirer." } }, { "@type": "Question", "name": "Le lévorphanol peut-il causer des problèmes cardiaques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Il peut provoquer des problèmes cardiaques chez certains patients, surtout en cas de surdose." } }, { "@type": "Question", "name": "Qui est à risque de dépendance au lévorphanol ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des antécédents de dépendance ou de troubles de l'humeur sont à risque." } }, { "@type": "Question", "name": "Les jeunes adultes sont-ils plus à risque avec le lévorphanol ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes adultes peuvent être plus susceptibles de développer une dépendance aux opioïdes." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'effets secondaires ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, les maladies chroniques et l'utilisation concomitante d'autres médicaments augmentent le risque." } }, { "@type": "Question", "name": "Le lévorphanol est-il risqué pour les femmes enceintes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut présenter des risques pour le fœtus et doit être évité sauf en cas de nécessité." } }, { "@type": "Question", "name": "Les personnes ayant des problèmes respiratoires sont-elles à risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont à risque accru de dépression respiratoire lors de l'utilisation de lévorphanol." } } ] } ] }

Sources (10000 au total)

Causal effect of COVID-19 on optic nerve and visual pathway disorders: genetic evidence of lung-brain axis.

To investigate the potential causal association between COVID-19 exposure and optic nerve and visual pathway disorders through a two-sample bidirectional Mendelian randomization (MR) analysis, and to ... This MR analysis utilized publicly accessible summary-level data from genome-wide association studies on COVID-19 (n=158,783) and optic nerve and visual pathway diseases (n=412,181), primarily involvi... In the forward analysis, the inverse-variance weighted method identified a significant causal effect of COVID-19 on optic nerve and visual pathway disorders (odds ratio = 1.697, 95% confidence interva... Our findings suggest that COVID-19 exposure may increase the risk of developing optic nerve and visual pathway disorders, supporting the lung-brain axis hypothesis. These results underscore the import...

Retinal structure and visual pathway function at school age in children born extremely preterm: a population-based study.

Children born extremely preterm (gestational age < 28 weeks) show reduced visual function even without any cerebral or ophthalmological neonatal diagnosis. In this study, we aimed to assess the retina... All children born extremely preterm from 2006-2011 (n = 65) in Central Norway were invited to participate. Thirty-six children (55%) with a median age of 13 years (range = 10-16) were examined with OC... Participants displayed abnormal retinal structure and P100 latencies (≥ 2 SD) compared to reference populations. Moreover, there was a negative correlation between P100 latency in large checks and RNF... Children born extremely preterm without preterm brain injury sequelae have signs of persistent immaturity of retinal vasculature and neuroretinal layers. Thinner neuroretinal layers are associated wit...

Age-related changes in the healthy adult visual pathway: evidence from diffusion tensor imaging with fixel-based analysis.

Fixel-based analysis (FBA) is a new method that overcomes the technical limitations of diffusion tensor imaging (DTI) by enabling the characterization of multiple fiber populations within a voxel, and... In this prospective cross-sectional study, brain DTI scans which were collected with more than six uniformly distributed gradient directions and higher b‑values (up to 2000 s/mm... Pearson's correlation analysis showed that DTI parameters of white matter (optic nerve, optic chiasma, optic tract, and optic radiation) in the optic pathway were correlated with age. FA values were n... FBA provides a useful method to assess age-related changes in the visual pathway, which is sensitive to diffusion. In addition, the b‑value influences DTI parameters and signal-to-noise ratio of the i...

Visual Pathway Involvement in NMDA Receptor Encephalitis: A Clinical, Optical Coherence Tomography, and 18-Fluorodeoxyglucose PET/CT Approach.

Anti-NMDA receptor (NMDAR) encephalitis patients have been reported to exhibit visual dysfunction without retinal thinning. The objective of our study was to examine the involvement of the visual path... In this cross-sectional study, patients diagnosed with anti-NMDAR encephalitis per consensus criteria underwent postrecovery visual acuity (VA) testing and optical coherence tomography (OCT) with auto... A total of 16 anti-NMDAR (32 eyes) and 32 HC (64 eyes) were included in the study. Anti-NMDAR exhibited lower low-contrast VA (2.5% contrast: -4.4 letters [95% CI; -8.5 to -0.3]; P = 0.04, 1.25% contr... Although the visual system seems to be involved in anti-NMDAR encephalitis, no retinal structural or occipital cortex functional abnormalities seem to be responsible for the visual dysfunction. When d...

Decreased spontaneous brain activity in the dorsal visual pathway in age-related macular degeneration patients revealed by fractional amplitude of low-frequency fluctuation.

Age-related macular degeneration (AMD) is the leading cause of visual loss in the developed world and damages the central retina. Growing evidences demonstrated that AMD patients were associated with ... The purpose of this study was to investigate the effect of central vision loss on spontaneous brain activity in AMD patients.... Seventeen AMD patients and 17 healthy controls (HCs) underwent resting-state MRI scans. The fractional amplitude of low-frequency fluctuations (fALFFs) was applied to investigate the spontaneous brain... Compared with HC group, AMD patients showed significant decreased fALFF values in the right calcarine/cuneus (brodmann area 17,8) and right superior parietal lobule (brodmann area 7).... Our results showed that AMD patients had decreased brain activities in the dorsal visual pathway, which offer important insights into the neural mechanisms of central visual field defect in AMD patien...

Pediatric reference values of anterior visual pathway structures measured with axis-correction on high-resolution 3D T2 fast spin echo sequences.

The size of the anterior visual pathway (AVP) structures is affected by patient age and pathology. Normative data is useful when determining whether pathology is present. AVP structures do not respect... For each patient 32 measurements of AVP structures were obtained in 145 children (2 months - 18 years) with normal brain MR studies on high-resolution 3D T2w FSE images adjusted to the axis of each AV... Descriptive statistics were compiled in a reference table and prediction plots in relation to age, height, and body surface area (BSA) were obtained from the best overall performing statistical model,... Detailed charts of reference values for AVP structures as well as prediction plots in relation to age, height and BSA were established using axis-corrected measurements from the MPR of high-resolution...